Plerixafor inhibits CXCR4, thus inducing the mobilization of hematopoietic stem/progenitor cells in lymphoma and multiple myeloma (MM) patients eligible for autologous stem cell transplantation (ASCT). However, the kinetics of plerixafor-induced mobilization of lymphocyte subsets is poorly known. Here, we evaluated the graft content, the engraftment, and the immunological reconstitution of MM patients receiving plerixafor. Thirty-seven patients undergoing one or tandem ASCT were enrolled. After mobilization with cyclophosphamide plus G-CSF, plerixafor was added at hematological recovery regardless of CD34+ cell count. We evaluated the number of CD34+, CD34+/CD38-, CD3+, CD4+, CD8+, CD19+, CD56+/CD3-, CD4+/CD25+/FOXP3+, and CD138+/CD38+ cells on each apheresis. Hematological and immunological recovery were determined at 30 days, 3, 6, 9, and 12 months after ASCT. Overall, 34/37 patients mobilized a median of 10.1 × 106 CD34+ cells/Kg (IQ 7.7-13.4). Patients with <20/µL CD34+ cells at plerixafor administration (18/33) had a significantly higher CD34+ cell fold increase, but not a higher absolute number, than 16/33 patients with ≥20/µL CD34+ cells. A similar CD34+ and immune graft composition was reported. A higher number of CD3+ and CD8+ cells/µL was observed at 3 months after first ASCT (p < 0.05) in the group with ≥20 CD34+ cells/µL. Thus, in MM patients, the timing of plerixafor administration influences immunological recovery.

中文翻译：

---

在多发性骨髓瘤中自体干细胞移植后，添加G-Csf和化学疗法的plerixa的时机会影响免疫学的恢复。

Plerixafor抑制CXCR4，从而在适合自体干细胞移植（ASCT）的淋巴瘤和多发性骨髓瘤（MM）患者中诱导造血干/祖细胞动员。然而，培来沙福诱导的淋巴细胞亚群动员的动力学知之甚少。在这里，我们评估了接受plerixafor的MM患者的移植物含量，移植物和免疫重建。纳入了37例接受一次或串联ASCT的患者。用环磷酰胺加G-CSF动员后，无论血液CD34 +细胞计数如何，在血液学恢复中均添加了plerixafor。我们评估了每个单采血液中CD34 +，CD34 + / CD38-，CD3 +，CD4 +，CD8 +，CD19 +，CD56 + / CD3-，CD4 + / CD25 + / FOXP3 +和CD138 + / CD38 +细胞的数量。在第3天，第6天，第9天，第30天确定血液和免疫学恢复 在ASCT之后的12个月。总体而言，有34/37名患者动员的中位数为10.1×106 CD34 +细胞/ Kg（IQ 7.7-13.4）。与使用≥20/ µL CD34 +细胞的16/33患者相比，在使用plerixafor进行治疗时（18/33）CD34 +细胞少于20 / µL的患者具有显着更高的CD34 +细胞倍数增加，但绝对数却没有更高。报道了相似的CD34 +和免疫移植物组成。≥20个CD34 +细胞/μL组中，首次ASCT后3个月时观察到更高数量的CD3 +和CD8 +细胞/μL（p <0.05）。因此，在MM患者中，使用plerixa的时机会影响免疫学恢复。但绝对值没有比16/33≥20 / µL CD34 +细胞的患者高。报道了相似的CD34 +和免疫移植物组成。≥20个CD34 +细胞/μL组中，首次ASCT后3个月时观察到更高数量的CD3 +和CD8 +细胞/μL（p <0.05）。因此，在MM患者中，使用plerixa的时机会影响免疫学恢复。但绝对值没有比16/33≥20 / µL CD34 +细胞的患者高。报道了相似的CD34 +和免疫移植物组成。≥20个CD34 +细胞/μL组中，首次ASCT后3个月时观察到更高数量的CD3 +和CD8 +细胞/μL（p <0.05）。因此，在MM患者中，使用plerixa的时机会影响免疫学恢复。